Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | MTAP | Q13126 | 14/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847064 | 1.00 | PNP (0.51) | PNPADORA2AMTAP | |
| SCHEMBL6381103 | 1.00 | PNP (0.51) | PNPADORA2AMTAP | |
| SCHEMBL13843355 | 1.00 | PNP (0.51) | PNPADORA2AMTAP | |
| SCHEMBL13847233 | 0.86 | MTAP (0.50) | PNPMTAP | |
| SCHEMBL13847179 | 0.85 | MTAP (0.52) | PNPMTAP | |
| SCHEMBL6938475 | 0.83 | ADORA2A (0.49) | PNPADORA2A | |
| SCHEMBL13847228 | 0.81 | MTAP (0.43) | PNPMTAP | |
| SCHEMBL13843356 | 0.81 | MTAP (0.43) | PNPMTAP | |
| SCHEMBL3986874 | 0.81 | ADORA2A (0.48) | PNPADORA2A | |
| SCHEMBL13843297 | 0.81 | ADORA2A (0.48) | PNPADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-7534767-B2 | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | claimed |
| CN-1968605-A | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2007-05-23 | — | — | CN | claimed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7534767-B2 | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534767-B2 | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| CN-1968605-A | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| WO-2007002191-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | PNP 8/4885ADORA2A 134/4885MTAP 5/4885 |
| US-20080021047-A1 | C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase | NSUN2, PNP, RNGTT | PNP 2/4885ADORA2A 106/4885MTAP 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.